- Eloxx Pharmaceuticals Inc To Host Investor and Analyst Call on Alport Syndrome TranscriptJun 27, 2023
- Eloxx Pharmaceuticals Inc Annual Shareholders Meeting TranscriptJun 22, 2023
- Eloxx Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 13, 2023
- Eloxx Pharmaceuticals Inc Topline ELX-02 Phase 2 Combination Results Call TranscriptSep 14, 2022
- Eloxx Pharmaceuticals Inc Topline ELX-02 Phase 2 Results Call and Webcast TranscriptNov 17, 2021
- Eloxx Pharmaceuticals Inc Analyst Call on Cystic Fibrosis Programs TranscriptOct 12, 2021
- Eloxx Pharmaceuticals, Inc., Zikani Therapeutics, Inc. - M&A Call TranscriptApr 01, 2021
- Q4 2020 Eloxx Pharmaceuticals Inc Earnings Call TranscriptMar 11, 2021$154.8 (+2.65%)Earnings
- Q3 2020 Eloxx Pharmaceuticals Inc Earnings Call TranscriptNov 05, 2020$108.8 (+4.21%)Earnings
- Q2 2020 Eloxx Pharmaceuticals Inc Earnings Call TranscriptAug 06, 2020$123.6 (-6.93%)Earnings
- Eloxx Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMay 20, 2020
- Q1 2020 Eloxx Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2020$116.4 (+14.12%)Earnings
- Q4 2019 Eloxx Pharmaceuticals Inc Earnings Call TranscriptMar 05, 2020$138 (-9.92%)Earnings
- Eloxx Pharmaceuticals, Inc. - Special Call TranscriptJan 14, 2020
- Q3 2019 Eloxx Pharmaceuticals Inc Earnings Call TranscriptNov 05, 2019$262 (-6.89%)Earnings
- Q2 2019 Eloxx Pharmaceuticals Inc Earnings Call TranscriptAug 07, 2019$242.8 (-9.40%)Earnings
- Q1 2019 Eloxx Pharmaceuticals Inc Earnings Call TranscriptMay 09, 2019$474 (+7.63%)Earnings
- Eloxx Pharmaceuticals Inc at Barclays Global Healthcare Conference TranscriptMar 14, 2019
- Q4 2018 Eloxx Pharmaceuticals Inc Earnings Call TranscriptMar 08, 2019$470.4 (+1.55%)Earnings
Q2 2020 Eloxx Pharmaceuticals Inc Earnings Call Transcript
Good afternoon, everyone, and welcome to the Eloxx Pharmaceuticals Second Quarter 2020 Earnings Webcast and Conference Call. Today's call is being recorded.
At this time, I would like to turn the call over to Barbara Ryan, Eloxx Investor Relations. Please begin.
Thank you. Welcome and thank you all for joining us this afternoon for a review of Eloxx Pharmaceuticals' Second Quarter 2020 Financial Results and Business Update. Joining me this afternoon are Dr. Greg Williams, our Chief Executive Officer; Neil Belloff, our Chief Operating Officer and General Counsel; Dr. Tom Haverty, our Chief Medical Officer; Dr. Matthew Goddeeris, our Vice President of Research; and Stephen MacDonald, our Vice President of Finance and Accounting. Before we begin, I'd like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)